Liver Disease脂肪肝ppt课件.ppt

Fatty Liver Disease;Disclosures;Objectives;Terminology;Fatty liver Normal liver;Statistics;By 2020;Natural History of FLDfatty liver steatohepatitis steatohepatitis + fibrosis   steatohepatitis + cirrhosiscryptogenic cirrhosis;Mortality risk:  Cirrhotics with NAFLD vs hepatitis C;NAFLD: risk factors;Risk factors: Established association;Risk factors: Emerging association;Risk factor: Medications;Risk factor: Bacteria overgrowth;Screening ConsiderationsAASLD rec’s;Further work-up indicated;NAFLD fibrosis score;NAFLD fibrosis score;Algorithm for evaluating NAFLD* *taken from AGA position paper 2002 ;Liver biopsyAASLD rec’s;Assessment;Management: Lifestyle Interventions;Lifestyle Interventions;ManagementMedications;Insulin sensitizing agents;PIVENS Study;Primary outcome;Secondary outcome;PIVEN Conclusions;AASLD recommendations:;Vitamin E: other concerns;Other meds for NASH;Statins;GREACE study*;AASLD Recommendation on Statins;Bariatric surgery;AASLD Recommendation on Bariatric Surgery;Transplant Considerations;MS Immunosuppression ;Metabolic Syndrome  in Kidney Transplant*;Metabolic Syndrome  in Kidney Transplant;Metabolic Syndrome  in Kidney Transplant;Metabolic Syndrome  in Kidney Transplant: Blood Pressure;Metabolic Syndrome  in Kidney Transplant: Hyperlipdemia;Risk factors for NASH after liver transplant*;MS Post Liver Transplant;MS Post Liver Transplant;MS Post Liver Transplant*;MS Post Liver Transplant*;MS and Heart Transplant*;;Impact of FLD on Donors;Special Considerations;NASH and Hepatocellular Carcinoma;Acute Fatty Liver Pregnancy;Pediatric Issues;Pediatric Issues;Pediatric Issues: screening;Pediatric Issues: treatment;Pediatric Issues: treatment;Pediatric Issues: treatment;AASLD Pediatric Recommendations;